Published in Clin Infect Dis on January 15, 2008
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother (2008) 4.21
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis (2009) 2.72
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis (2013) 2.44
Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother (2010) 2.34
Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev (2012) 2.18
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol (2008) 2.07
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol (2009) 2.00
Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci (2012) 1.91
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.80
Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis (2011) 1.78
Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 1.53
Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother (2008) 1.51
Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob (2009) 1.50
Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol (2008) 1.49
Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother (2009) 1.47
Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother (2009) 1.47
Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J (2009) 1.43
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 1.38
Staphylococcus aureus nasal colonization and subsequent infection in intensive care unit patients: does methicillin resistance matter? Infect Control Hosp Epidemiol (2010) 1.34
Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc (2011) 1.33
Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med (2011) 1.32
Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J Mol Med (Berl) (2013) 1.30
Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods. J Clin Microbiol (2011) 1.29
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis (2010) 1.26
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.23
Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect (2013) 1.23
High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg Infect Dis (2011) 1.22
Predicting risk for death from MRSA bacteremia. Emerg Infect Dis (2012) 1.22
Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology (2011) 1.21
Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother (2009) 1.17
Community-associated versus healthcare-associated methicillin-resistant Staphylococcus aureus bacteraemia: a 10-year retrospective review. Eur J Clin Microbiol Infect Dis (2008) 1.16
Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One (2011) 1.16
Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther (2010) 1.15
Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol (2010) 1.14
Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol (2011) 1.12
In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2011) 1.12
Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.11
High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis (2012) 1.11
Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis (2009) 1.11
Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. Expert Rev Anti Infect Ther (2010) 1.11
The epidemiology of hematogenous vertebral osteomyelitis: a cohort study in a tertiary care hospital. BMC Infect Dis (2010) 1.11
Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis (2009) 1.10
Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy (2011) 1.09
Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.09
Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review. J Pediatr Pharmacol Ther (2009) 1.09
Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep (2012) 1.08
Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis (2010) 1.07
Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol (2012) 1.07
Multicenter evaluation of the clinical outcomes of daptomycin with and without concomitant β-lactams in patients with Staphylococcus aureus bacteremia and mild to moderate renal impairment. Antimicrob Agents Chemother (2012) 1.07
Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother (2012) 1.05
Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother (2009) 1.05
Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2011) 1.05
Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J Clin Microbiol (2010) 1.03
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother (2008) 1.03
Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2013) 1.02
Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol (2010) 1.02
Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore) (2013) 1.00
Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2009) 0.99
Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis (2012) 0.99
Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods. J Clin Microbiol (2013) 0.99
The Japanese guidelines for the management of sepsis. J Intensive Care (2014) 0.99
Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2008) 0.98
Current and novel antibiotics against resistant Gram-positive bacteria. Infect Drug Resist (2008) 0.98
Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother (2008) 0.97
Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades. Eur J Clin Microbiol Infect Dis (2011) 0.97
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis (2014) 0.96
An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis (2011) 0.96
USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit. J Clin Microbiol (2010) 0.96
Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care (2011) 0.96
The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia. BMC Infect Dis (2011) 0.92
Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: a clinically useful risk stratification tool. Antimicrob Agents Chemother (2011) 0.92
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol (2011) 0.92
Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia. Int J Microbiol (2010) 0.91
Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2011) 0.91
Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis (2011) 0.91
Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin. J Clin Microbiol (2011) 0.91
Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III. PLoS One (2012) 0.90
Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro. Antimicrob Agents Chemother (2013) 0.90
Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study. Korean J Intern Med (2013) 0.90
Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2011) 0.89
Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis (2010) 0.89
Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist (2012) 0.88
Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2010) 0.88
Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. Crit Care (2009) 0.87
Development and stability studies of novel liposomal vancomycin formulations. ISRN Pharm (2012) 0.87
Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital. BMC Res Notes (2013) 0.86
Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther (2014) 0.86
Molecular epidemiology and characteristic of virulence gene of community-acquired and hospital-acquired methicillin-resistant Staphylococcus aureus isolates in Sun Yat-sen Memorial hospital, Guangzhou, Southern China. BMC Infect Dis (2016) 0.86
No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates. Pediatr Infect Dis J (2014) 0.86
Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2012) 0.86
Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.86
Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis (2011) 0.85
New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies. Mediterr J Hematol Infect Dis (2015) 0.85
Genetic basis of rifampicin resistance in methicillin-resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa. BMC Microbiol (2012) 0.84
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract (2009) 0.84
Underestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing. Infect Chemother (2014) 0.84
Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients. BMC Infect Dis (2015) 0.83
Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clin J Am Soc Nephrol (2010) 0.82
Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest (2013) 2.19
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis (2003) 2.13
Clinical consequences of infection in patients with acute stroke: is it prime time for further antibiotic trials? Stroke (2005) 1.91
Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med (2006) 1.89
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
[Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study]. Enferm Infecc Microbiol Clin (2005) 1.77
Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest (2007) 1.77
Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis (2002) 1.70
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med (2007) 1.69
Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother (2011) 1.60
Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased? Chest (2006) 1.58
Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med (2012) 1.54
Mitochondrial toxicity associated with linezolid. N Engl J Med (2005) 1.52
First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother (2011) 1.48
Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc (2015) 1.48
The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia. Am J Respir Crit Care Med (2015) 1.46
Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax (2011) 1.39
Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother (2006) 1.38
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis (2008) 1.37
Quinolone-resistant uropathogenic Escherichia coli strains from phylogenetic group B2 have fewer virulence factors than their susceptible counterparts. J Clin Microbiol (2005) 1.36
Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? Clin Infect Dis (2003) 1.32
Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother (2012) 1.31
In vitro antimicrobial susceptibility of clinical isolates of Aeromonas caviae, Aeromonas hydrophila and Aeromonas veronii biotype sobria. J Antimicrob Chemother (2002) 1.29
The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther (2006) 1.28
Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med (2002) 1.27
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.23
Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol (2002) 1.23
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.21
Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (2012) 1.20
First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 beta-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother (2011) 1.17
Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother (2011) 1.17
Development of imipenem resistance in an Aeromonas veronii biovar sobria clinical isolate recovered from a patient with cholangitis. J Med Microbiol (2009) 1.16
HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One (2013) 1.13
Phylogenetic analysis of viridans group streptococci causing endocarditis. J Clin Microbiol (2008) 1.10
Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis (2008) 1.09
Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care (2011) 1.09
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (2012) 1.08
High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn Microbiol Infect Dis (2002) 1.08
Mechanism of resistance to several antimicrobial agents in Salmonella Clinical isolates causing traveler's diarrhea. Antimicrob Agents Chemother (2004) 1.07
Neglecting Enterococci May Lead to a Misinterpretation of the Consequences of Last Changes in Endocarditis Prophylaxis American Heart Association Guidelines. J Am Coll Cardiol (2015) 1.07
Usefulness of histological analysis for predicting the presence of microorganisms at the time of reimplantation after hip resection arthroplasty for the treatment of infection. J Bone Joint Surg Am (2007) 1.07
Present epidemiology of tuberculosis. Prevention and control programs. Enferm Infecc Microbiol Clin (2011) 1.06
Identification of clinically relevant Corynebacterium spp., Arcanobacterium haemolyticum, and Rhodococcus equi by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol (2012) 1.06
Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother (2009) 1.06
Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol (2006) 1.06
Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother (2007) 1.05
Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother (2002) 1.03
Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. J Antimicrob Chemother (2002) 1.02
Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother (2009) 1.02
In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine. Diagn Microbiol Infect Dis (2002) 1.02
Potential virulence and antimicrobial susceptibility of Aeromonas popoffii recovered from freshwater and seawater. FEMS Immunol Med Microbiol (2002) 1.02
Neutrophils in frozen section and type of microorganism isolated at the time of resection arthroplasty for the treatment of infection. Arch Orthop Trauma Surg (2008) 1.01
Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain. J Infect (2011) 1.00
Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol (2006) 0.99
Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother (2013) 0.99
Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin (2011) 0.98
Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol (2004) 0.95
Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infect (2012) 0.94
Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol (2008) 0.93
Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci. Int J Antimicrob Agents (2011) 0.91
Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother (2002) 0.91
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother (2013) 0.91
Genotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markers. Antimicrob Agents Chemother (2008) 0.91
[Listeria monocytogenes bacteremia: analysis of 110 episodes]. Med Clin (Barc) (2007) 0.91
Pandemic influenza A(H1N1) outbreak among a group of medical students who traveled to the Dominican Republic. J Travel Med (2011) 0.90
Triage flowchart to rule out acute coronary syndrome. Am J Emerg Med (2007) 0.90
Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med (2008) 0.90
Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother (2008) 0.89
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control (2009) 0.89
Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis (2012) 0.88